Company Description
Merck & Co., Inc. operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications.
It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.
The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Country | United States |
| Founded | 2000 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 72,000 |
| CEO | Robert Davis |
Contact Details
Address: 126 East Lincoln Avenue Rahway, New Jersey 07065 United States | |
| Phone | 908 740 4000 |
| Website | merck.com |
Stock Details
| Ticker Symbol | MRK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000310158 |
| CUSIP Number | 58933Y105 |
| ISIN Number | US58933Y1055 |
| Employer ID | 22-1918501 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Davis | Chief Executive Officer |
| Caroline Litchfield | Chief Financial Officer |
| Peter Dannenbaum | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 3 | Initial statement of beneficial ownership of securities |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 25-NSE | Filing |
| Oct 31, 2024 | 8-K | Current Report |
| Aug 5, 2024 | 10-Q | Quarterly Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 25, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 25, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |